ProPhase Labs, Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Earnings Per Share (Tables)

Earnings Per Share (Tables)

6 Months Ended

Jun. 30, 2023

Schedule of Basic and Diluted Net Loss Per Share

The following is a reconciliation of the weighted average number of common shares outstanding used in calculating basic and diluted net loss per share (in thousands):


	For the three months ended				For the six months ended
	June 30, 2023		June 30, 2022		June 30, 2023		June 30, 2022
Net (loss) income - basic	$	(3,440)	$	7,446	$	(2,890)	$	19,940
Interest on unsecured convertible promissory note	—		200		—		432
Net (loss) income - diluted	$	(3,440)	$	7,646	$	(2,890)	$	20,372

Weighted average shares outstanding - basic	16,845		15,576		16,797		15,531
Diluted shares- Stock Options	—		2,635		—		2,389
Diluted shares- Stock Warrants	—		261		—		244
Unsecured convertible promissory note	—		800		—		800
Weighted average shares outstanding - diluted	16,845		19,272		16,797		18,964

Schedule of Anti-dilutive Securities Excluded from the Income Per Share Computation

The following table represents the number of securities excluded from the income per share computation as a result of their anti-dilutive effect (in thousands):


	For the three months ended		For the three months ended
Anti-dilutive securities	June 30, 2023	June 30, 2022	June 30, 2023	June 30, 2022
Common stock purchase warrants	1,231	455	1,231	455
Stock Options	3,691	275	3,691	275

Anti-dilutive securities	4,922	730	4,922	730